MBRX Stock Overview
A clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Moleculin Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.62 |
| 52 Week High | US$15.75 |
| 52 Week Low | US$2.12 |
| Beta | 1.86 |
| 11 Month Change | 1.75% |
| 3 Month Change | 4.38% |
| 1 Year Change | -69.88% |
| 33 Year Change | -91.56% |
| 5 Year Change | -97.17% |
| Change since IPO | -99.64% |
Recent News & Updates
Recent updates
We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate
Dec 20
Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?
Jul 14Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?
Feb 18Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
Nov 01Moleculin Biotech rises 7% as WP1096 compound selected for NIAID-funded animal studies
Sep 27Moleculin brain cancer therapy WP1122 gets FDA orphan drug status
Sep 06Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
Jul 11Moleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trial
Jul 08We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth
Mar 28We're Not Very Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate
Dec 11We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth
Aug 18Moleculin Biotech to join Russell 2000 Index
Jun 15Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Invest In Growth?
May 04Shareholder Returns
| MBRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.2% | 4.0% | 2.0% |
| 1Y | -69.9% | 18.0% | 32.4% |
Return vs Industry: MBRX underperformed the US Biotechs industry which returned 18.3% over the past year.
Return vs Market: MBRX underperformed the US Market which returned 32.6% over the past year.
Price Volatility
| MBRX volatility | |
|---|---|
| MBRX Average Weekly Movement | 12.4% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MBRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MBRX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 18 | Wally Klemp | moleculin.com |
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers.
Moleculin Biotech, Inc. Fundamentals Summary
| MBRX fundamental statistics | |
|---|---|
| Market cap | US$7.96m |
| Earnings (TTM) | -US$30.15m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs MBRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MBRX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$30.15m |
| Earnings | -US$30.15m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -10.04 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MBRX perform over the long term?
See historical performance and comparison